Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders

GBT (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.

Year Invested: 2012
Location: South San Francisco, Calif.

Recent News

March 15, 2018
GBT Announces New Employment Inducement Grants

March 12, 2018
Global Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

March 8, 2018
Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock

Read More News

Associated Team Members

Glenn Pierce, M.D., Ph.D.

Charles Homcy, M.D.

Craig Muir
Partner/Chief Technology Officer

Kevin Starr